Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H28N2O.ClH |
| Molecular Weight | 324.889 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCCN1CCCC1C(=O)NC2=C(C)C=C(C)C=C2C
InChI
InChIKey=NFEZGTHMTGKIBG-UHFFFAOYSA-N
InChI=1S/C18H28N2O.ClH/c1-5-6-9-20-10-7-8-16(20)18(21)19-17-14(3)11-13(2)12-15(17)4;/h11-12,16H,5-10H2,1-4H3,(H,19,21);1H
Bumecaine (Pyromecaine) is a local anesthetic and anti-arrhythmic drug. It is indicated as an agent for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. The experiments on the isolated neurons in the rat spinal ganglions have shown that interaction of pyromecaine with inactivated Na+ channels makes a considerable contribution to the blocking effect of anesthesia. Oral administration of pyromecaine pills considerably depresses platelet aggregation and even causes platelet disaggregation. Possible side effects are: general weakness, nausea, vomiting, headache, dizziness, fainting, a drop in blood pressure. Quinidine increases the risk of side effects.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Sodium channels |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Bumecain Approved UsePyromecaine is prescribed as an anesthetic for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. Pyromecaine is also used as an antiarrhythmic agent. |
|||
| Primary | Bumecain Approved UsePyromecaine is prescribed as an anesthetic for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. Pyromecaine is also used as an antiarrhythmic agent. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Anti-arrhythmia properties of pyromecaine]. | 1983 Sep-Oct |
|
| [Effect of anti-angina therapy on phospholipid levels of the myocardium in ischemic lesions]. | 1988 Oct |
|
| [Interaction of quinidine, lidocaine, tricaine and pyromecaine with heparin]. | 1989 Jul-Aug |
|
| [The Ca2+ reactivity and the subunit composition of myocardial actomyosin during the pyromecaine and pyrroxan treatment of experimental ischemia]. | 1990 Jan-Feb |
|
| [The action of aqueous solutions of dicaine and pyromecaine on the epithelium of the oral mucosa]. | 1990 May-Jun |
|
| [A morphological evaluation of the tissue status of the oral mucosa after anesthesia applied with dicaine and pyromecaine solutions]. | 1990 Nov-Dec |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
PBE1H9OIFQ
Created by
admin on Sat Dec 16 02:01:20 GMT 2023 , Edited by admin on Sat Dec 16 02:01:20 GMT 2023
|
PRIMARY | |||
|
DTXSID00940679
Created by
admin on Sat Dec 16 02:01:20 GMT 2023 , Edited by admin on Sat Dec 16 02:01:20 GMT 2023
|
PRIMARY | |||
|
19089-24-8
Created by
admin on Sat Dec 16 02:01:20 GMT 2023 , Edited by admin on Sat Dec 16 02:01:20 GMT 2023
|
PRIMARY | |||
|
167785
Created by
admin on Sat Dec 16 02:01:20 GMT 2023 , Edited by admin on Sat Dec 16 02:01:20 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
